
Pfizer will co-develop and commercialise OPKO’s growth hormone deficiency (GHD) drug hGH-CTP in a new agreement between the firms. The …
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer

